Mangoceuticals, Inc. MGRX
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 1.33% | -28.07% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 1.33% | -28.07% | |||
| Cost of Revenue | -37.02% | -17.06% | |||
| Gross Profit | 52.41% | -38.95% | |||
| SG&A Expenses | -65.72% | 662.28% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -65.37% | 101.13% | |||
| Operating Income | 66.83% | -109.34% | |||
| Income Before Tax | 61.42% | -22.88% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 61.42% | -22.88% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | 100.00% | |||
| Net Income | 61.43% | -22.88% | |||
| EBIT | 66.83% | -109.34% | |||
| EBITDA | 73.84% | -171.56% | |||
| EPS Basic | 58.18% | -3.89% | |||
| Normalized Basic EPS | 62.90% | -94.14% | |||
| EPS Diluted | 58.18% | -3.89% | |||
| Normalized Diluted EPS | 62.90% | -94.14% | |||
| Average Basic Shares Outstanding | 3.87% | 16.16% | |||
| Average Diluted Shares Outstanding | 3.87% | 16.16% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||